Schistosomiasis

Merck Continues the Fight against Schistosomiasis in a Storytelling Lab

Retrieved on: 
火曜日, 4月 2, 2024

Merck, a leading science and technology company, announced the winners of its 2024 Bilharzia Storytelling Lab in Ethiopia.

Key Points: 
  • Merck, a leading science and technology company, announced the winners of its 2024 Bilharzia Storytelling Lab in Ethiopia.
  • This innovative initiative aims to develop creative solutions in order to raise awareness about schistosomiasis and, in doing so, bring about behavioral change.
  • View the full release here: https://www.businesswire.com/news/home/20240402803315/en/
    The winners of this year's Merck Bilharzia Storytelling Lab in Ethiopia (Photo: Business Wire)
    Schistosomiasis is one of the most prevalent parasitic diseases and affects more than 240 million people worldwide.
  • Read more about how Merck is committed to eliminating schistosomiasis: www.merckgroup.com/schistosomiasis
    View source version on businesswire.com: https://www.businesswire.com/news/home/20240402803315/en/

EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children

Retrieved on: 
月曜日, 12月 18, 2023

TOKYO, Dec. 18, 2023 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund has supported the Pediatric Praziquantel Consortium's development of arpraziquantel since 2013 through a total investment of approximately 1.85 billion Japanese yen. On December 15, the Consortium announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive scientific opinion for arpraziquantel to treat schistosomiasis in preschool-aged children. Arpraziquantel is the first investigational drug to receive positive scientific opinion amongst the projects funded by the GHIT Fund. Present in 78 countries and endemic in 51, schistosomiasis affects more than 240 million people, about 50 million of whom are preschool-aged children. Leveraging Japanese innovation and leadership in the global fight against neglected tropical diseases (NTDs), GHIT Fund invests in global health R&D and facilitates transformational cross-border public-private partnerships.

Key Points: 
  • On December 15, the Consortium announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive scientific opinion for arpraziquantel to treat schistosomiasis in preschool-aged children.
  • Present in 78 countries and endemic in 51, schistosomiasis affects more than 240 million people, about 50 million of whom are preschool-aged children.
  • Extending the range of options for the treatment of schistosomiasis, arpraziquantel is tailored for preschool-aged children against Schistosoma mansoni and Schistosoma haematobium.
  • Its mission is to develop, register, and provide access to a suitable pediatric drug for treating schistosomiasis in children 3 months to 6 years of age.

EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children

Retrieved on: 
日曜日, 12月 17, 2023

TOKYO, Dec. 17, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") contributed to the development of a pediatric formulation to treat schistosomiasis as a member of the Pediatric Praziquantel Consortium (Consortium). The Consortium announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive scientific opinion for arpraziquantel to treat one of the neglected tropical diseases, schistosomiasis, in preschool-aged children (3 months to 6 years of age) on December 15. EMA assessed arpraziquantel under the EU-Medicines for all (EU-M4all) *1 procedure for high-priority medicines intended for use in countries outside the European Union. For more details on arpraziquantel, please refer to the Consortium's press release.

Key Points: 
  • EMA assessed arpraziquantel under the EU-Medicines for all (EU-M4all) *1 procedure for high-priority medicines intended for use in countries outside the European Union.
  • For more details on arpraziquantel, please refer to the Consortium's press release .
  • Astellas provided its innovative formulation technology to co-develop arpraziquantel as a member of the Consortium.
  • Initiatives in the Consortium apply to (3), and the positive CHMP scientific opinion by EMA of arpraziquantel represents a significant milestone in alignment with Astellas' Access to Health focus.

From fatal allergies to heart attacks and cholera – the devastating health effects of global warming in Africa

Retrieved on: 
水曜日, 9月 6, 2023

Wild fires create their own weather systems, generating fire storms with devastating effects.

Key Points: 
  • Wild fires create their own weather systems, generating fire storms with devastating effects.
  • Global warming will increase the number of days of shimmering heat, creating the ideal conditions for fire.
  • Global warming and El Niño combined suggest that the years ahead will result in increasing, devastating impacts.

Heat, air quality and health

    • High temperatures cause heat stroke, heat exhaustion, heart attacks, strokes and other cardiovascular disease.
    • People in informal settlements, and badly maintained and crowded buildings, are especially vulnerable to heat stress.

Less food, lower nutrition

    • In South Africa, drought recurrently affects subsistence agriculture, livestock and commercial crops.
    • The impact of drought on food and nutrition will be felt by the most vulnerable, including infants, small children and pregnant women and those who already live on or below the poverty line.
    • Crop failure and drought, combined with increased food costs associated with disruptions to global food resources, will affect every one of us.

Every drop counts

    • Humans require adequate hydration to survive, and the combination of increasing temperatures and water shortages heightens the risk of organ failure and death.
    • In addition, dependence on poor quality and contaminated water has an impact on household and personal hygiene, and intestinal infections.

Neglected diseases

    • Other viral and bacterial infectious diseases, especially prevalent in Africa, are also likely to increase with global warming.
    • Bundled together as “neglected diseases of poverty”, these include both parasitic and viral vector borne diseases such as Rift Valley fever, malaria, filariasis, schistosomiasis, dengue fever, chikungunya and influenza as well as arboviruses such as different influenza pathogens.

So where does this leave us?

    • When the Intergovernmental Panel on Climate Change was established in 1988, we had a choice to interrupt climate change and slow global warming.
    • This does not mean there is nothing we can do to halt the destruction of planetary life.

The European Medicines Agency (EMA) Validated Regulatory Application for Arpraziquantel, a Potential Treatment for Schistosomiasis in Preschool-Aged Children

Retrieved on: 
月曜日, 1月 23, 2023

Arpraziquantel, developed by the Pediatric Praziquantel Consortium, is a potential new treatment option tailored to improve child health by filling the treatment gap of an estimated 50 million preschool-aged children with schistosomiasis.

Key Points: 
  • Arpraziquantel, developed by the Pediatric Praziquantel Consortium, is a potential new treatment option tailored to improve child health by filling the treatment gap of an estimated 50 million preschool-aged children with schistosomiasis.
  • On behalf of the Pediatric Praziquantel Consortium, Merck submitted the regulatory application for arpraziquantel to the European Medicines Agency (EMA), which validated this application and started the scientific review process in December 2022.
  • Arpraziquantel represents the first investigational drug that has reached the regulatory phase amongst the portfolio of projects supported by GHIT Fund.
  • The drug praziquantel – the current standard treatment developed in the 1970s – is safe, effective and available for school-aged children and adults.

Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases

Retrieved on: 
水曜日, 11月 30, 2022

SHANGHAI, China and SEOUL, Republic of Korea, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutics, and the International Vaccine Institute, an international nonprofit organization devoted to providing vaccines critical to global public health and based in Seoul, Korea, today announced that Clinical Infectious Diseases has published additional data from SPECTRA, a global Phase 2/3 clinical trial, that showed vaccination with SCB-2019 (CpG 1018/Alum) reduced the risk of transmitting SARS-CoV-2 infection to household members, compared to placebo participants.

Key Points: 
  • Among the 134 household contacts of infected household members who had received SCB-2019, there was one case of COVID-19; among the 250 household contacts of infected household members who were not vaccinated, there were 12 cases.
  • There were no cases of symptomatic SARS-CoV-2 infection among household contacts who were partially or fully vaccinated and where the infected household member was vaccinated with SCB-2019.
  • This indicates that SCB-2019 vaccination reduced household transmission and that vaccinated household contacts also likely benefited from the protection provided by their own vaccination.
  • The study team was blinded to the assignment of SPECTRA participants to vaccine or placebo groups.

Lemonex, IVI Exchange MOU on Joint Vaccine Development

Retrieved on: 
木曜日, 11月 10, 2022

The International Vaccine Institute (IVI) announced on November 10th it signed a memorandum of understanding (MOU) with Lemonex, a company specializing in RNA gene therapy development, and agreed to seek cooperation in research and development.

Key Points: 
  • The International Vaccine Institute (IVI) announced on November 10th it signed a memorandum of understanding (MOU) with Lemonex, a company specializing in RNA gene therapy development, and agreed to seek cooperation in research and development.
  • IVI and Lemonex have agreed to join forces to introduce DegradaBALL drug delivery technology to the development of infectious disease vaccines and advance vaccine development by using IVIs extensive expertise in all areas of vaccine development.
  • The two organizations plan to utilize Lemonex's expertise in vaccine development and drug delivery platform, and rapidly develop a safe and effective mRNA vaccine through mutual cooperation by using IVI's extensive experience in clinical development and epidemiology.
  • Cheolhee Won, CEO of Lemonex, said, We are proud to have established a vaccine R&D partnership with IVI to develop an mRNA vaccine.

Global Access Diagnostics (GADx) Formed to Expand Affordable Access to Advanced Rapid Diagnostic Technologies

Retrieved on: 
水曜日, 6月 15, 2022

Global Access Health (GAH), a social enterprise dedicated to providing affordable medical products for global health, today formally introduced its first portfolio company, Global Access Diagnostics (GADx).

Key Points: 
  • Global Access Health (GAH), a social enterprise dedicated to providing affordable medical products for global health, today formally introduced its first portfolio company, Global Access Diagnostics (GADx).
  • GADx has been created to address gaps in the global provision of diagnostics with a focus on expanding affordable access to quality tests.
  • The Company combines expertise in rapid diagnostics development from Mologic Ltd with low-cost manufacturing and scale-up capability of sister company, Global Access Diagnostics (GAD).
  • Through this transaction, the group acquired Mologic and GAD to harness industry-leading expertise in developing and manufacture of rapid diagnostic technologies.

Watch Advancements on Saturday, June 18 at 8:00 PM ET on Bloomberg

Retrieved on: 
月曜日, 6月 13, 2022

JUPITER, Fla., June 13, 2022 /PRNewswire-PRWeb/ -- Advancements with Ted Danson is scheduled to broadcast on Saturday, June 18, 2022, at 8:00 PM ET on Bloomberg. Check local listings for more information.

Key Points: 
  • JUPITER, Fla., June 13, 2022 /PRNewswire-PRWeb/ -- Advancements with Ted Danson is scheduled to broadcast on Saturday, June 18, 2022, at 8:00 PM ET on Bloomberg.
  • Advancements will also explore how information sharing and collaborative analysis are being used to secure IT infrastructure.
  • "We are thrilled to share this vital information with audiences and look forward to watching on Saturday," said Dustin Schwarz, Programming Director for DMG Productions and the Advancements series.
  • About Advancements and DMG Productions:
    Advancements is an information-based educational television series that explores recent developments taking place across several industries and economies.

Advancements to Explore Developments in HPV prevention through Synergized disease response for families

Retrieved on: 
金曜日, 11月 19, 2021

In addition to learning about the world-wide phenomenon, HPV, the segment will also explore the urogenital schistosomiasis endemic in Africa.

Key Points: 
  • In addition to learning about the world-wide phenomenon, HPV, the segment will also explore the urogenital schistosomiasis endemic in Africa.
  • Spectators will learn why 110 million young women in sub-Saharan Africa are also at risk of female genital schistosomiasis (FGS), a disease, which might look like cancer or a sexually transmitted disease.
  • The show will also explore how HPV Global Action is working across the globe through the dissemination of critical, evidence-based information.
  • About Advancements and DMG Productions:
    The Advancements series is an information-based educational show targeting recent advances across a number of industries and economies.